United-Guardian | 8-K: FY2025 Q3 Revenue: USD 2.264 M

Revenue: As of FY2025 Q3, the actual value is USD 2.264 M.

EPS: As of FY2025 Q3, the actual value is USD 0.06.

EBIT: As of FY2025 Q3, the actual value is USD 139.91 K.

Net Sales: For the nine-month period ended September 30, 2025, net sales were $7,583,613, a decrease from $9,705,262 in 2024. For the third quarter, net sales were $2,264,261, down from $3,060,113 in 2024.

Net Income: For the nine-month period ended September 30, 2025, net income was $1,456,162 ($0.32 per share), a decrease from $2,747,151 ($0.60 per share) in 2024. For the third quarter, net income was $268,441 ($0.06 per share), down from $865,484 ($0.19 per share) in 2024.
Cost of Sales: For the nine-month period ended September 30, 2025, cost of sales was $3,775,122, a decrease from $4,526,446 in 2024. For the third quarter, cost of sales was $1,311,192, down from $1,408,866 in 2024.
Operating Expenses: For the nine-month period ended September 30, 2025, operating expenses were $1,947,678, an increase from $1,762,689 in 2024. For the third quarter, operating expenses were $620,893, up from $591,047 in 2024.
Research and Development Expense: For the nine-month period ended September 30, 2025, research and development expense was $339,366, an increase from $325,714 in 2024. For the third quarter, research and development expense was $117,104, up from $111,072 in 2024.
Income from Operations: For the nine-month period ended September 30, 2025, income from operations was $1,521,447, a decrease from $3,090,413 in 2024. For the third quarter, income from operations was $215,072, down from $949,128 in 2024.
Total Costs and Expenses: For the nine-month period ended September 30, 2025, total costs and expenses were $6,062,166, a decrease from $6,614,849 in 2024. For the third quarter, total costs and expenses were $2,049,189, down from $2,110,985 in 2024.

Investment Income: For the nine-month period ended September 30, 2025, investment income was $230,425, a decrease from $298,014 in 2024. For the third quarter, investment income was $75,165, down from $99,934 in 2024.
Net Gain on Marketable Securities: For the nine-month period ended September 30, 2025, net gain on marketable securities was $73,164, a decrease from $79,218 in 2024. For the third quarter, net gain on marketable securities was $36,238, down from $47,223 in 2024.
Total Other Income: For the nine-month period ended September 30, 2025, total other income was $303,589, a decrease from $377,232 in 2024. For the third quarter, total other income was $111,403, down from $147,157 in 2024.

Provision for Income Taxes: For the nine-month period ended September 30, 2025, provision for income taxes was $368,874, a decrease from $720,494 in 2024. For the third quarter, provision for income taxes was $58,034, down from $230,801 in 2024.

United-Guardian is optimistic about increasing sales of Renacidin®, their most important pharmaceutical product, by working with an outside pharmaceutical consultant to have it included on additional drug formularies. They are also hopeful that new marketing agreements for some of their new personal care products will provide an excellent opportunity to increase revenue in the coming years.